Intra-Cellular Therapies, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Intra-Cellular Therapies, Inc. - overview
Established
2002
Location
Bedminster, NJ, US
Primary Industry
Biotechnology
About
Based in New York, US, and founded by Sharon Mates (Chairman and CEO) in 2001, Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company developing target mechanism to counter the progression of Alzheimer's Disease. In January 2014, Intra-Cellular Therapies, Inc raised USD 107. 49 million in an IPO, selling 6.
14 million shares on the NASDAQ. Further in January 2022, the firm raised USD 400 million in a Private Placement selling 9. 52 million shares on the NASDAQ. The firm trades under the ticker symbol ITCI.
In January 2025, Johnson & Johnson, Inc. agreed to fully acquire Intra-Cellular Therapies, Inc. from Broadfin Capital, Tech Council Ventures, Alexandria Real Estate Equities, and Alafi Capital, for approximately USD 14. 6 billion.
The company’s flagship product, CAPLYTA® (lumateperone), is FDA-approved for treating schizophrenia and bipolar depression, offering a unique mechanism of action that combines efficacy with a favorable safety profile. Intra-Cellular Therapies' pipeline includes: ITI-1284 ODT-SL for generalized anxiety and agitation in Alzheimer’s patients, ITI-333 for opioid use disorder and mood disorders, and the ITI-1500 series, featuring non-hallucinogenic psychedelics aimed at mood disorders. In addition to these, the company is advancing PDE1 inhibitors like lenrispodun (ITI-214) for Parkinson’s disease and ITI-1020 for cancer immunotherapy.
Current Investors
Broadfin Capital, Deerfield Management, Alafi Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.intracellulartherapies.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Intra-Cellular Therapies, Inc. - timeline of key events
Intra-Cellular Therapies, Inc. - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Mar 31, 2013 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 23,400,000 | 3,100,000 | - | 2,737,002 | 577,301 | 91,364 | 330,702 | 245,837 | - | 60,613 | 22,812,979 | 83,803,017 | - | - | - |
| % Revenue Growth (YoY) | - | (86.8%) | - | - | - | (84.2%) | 262.0% | (25.7%) | (100.0%) | - | 37537.1% | 267.3% | - | - | - |
| EBITDA (USD) | 11,100,000 | (16,400,000) | (32,100) | (26,243,603) | (30,961,242) | (105,674,370) | (118,062,019) | (102,626,257) | (161,898,095) | (153,534,729) | (230,699,513) | (285,154,765) | - | - | - |
| Operating Income (USD) | 11,100,000 | (16,400,000) | (32,100) | (26,266,852) | (30,986,723) | (105,813,996) | (118,258,891) | (102,840,129) | (162,266,768) | (154,011,850) | (231,227,631) | (285,688,125) | - | - | - |
| Operating Margin | 47.4% | (529.0%) | - | (959.7%) | (5367.5%) | (115815.9%) | (35760.0%) | (41832.6%) | - | (254090.5%) | (1013.6%) | (340.9%) | - | - | - |
| % EBITDA Margin | 47.4% | (529.0%) | - | (958.8%) | (5363.1%) | (115663.0%) | (35700.4%) | (41745.7%) | - | (253303.3%) | (1011.3%) | (340.3%) | - | - | - |
| NET Income (USD) | 11,100,000 | (16,600,000) | (32,100) | (26,868,198) | (30,691,460) | (104,793,141) | (116,426,268) | (97,773,414) | (155,127,411) | (147,722,178) | (227,005,663) | (284,125,666) | - | - | - |
| % Net Margin | 47.4% | (535.5%) | - | (981.7%) | (5316.4%) | (114698.5%) | (35205.8%) | (39771.6%) | - | (243713.7%) | (995.1%) | (339.0%) | - | - | - |
Intra-Cellular Therapies, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Intra-Cellular Therapies, Inc. | - |
Displaying 1 - 1 of 1
Intra-Cellular Therapies, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.